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Abstract 
Maintenance of telomere length during cell division is dependent on the catalytic subunit 
telomerase reverse transcriptase (TERT), which adds TTAGGG repeats to the ends of 
chromosomes to prevent telomere shortening during DNA replication. However, non-
telomeric roles of TERT have emerged under oxidative stress whereby TERT translocates 
from the nucleus to the mitochondria and protects against mitochondrial dysfunction through 
a poorly defined mechanism. A major pathological feature of Alzheimer’s Disease (AD) is 
the progressive accumulation of amyloid-beta (Aβ) peptide within the cortex and 
hippocampus. Aβ can directly interfere with mitochondrial respiration and promote 
mitochondrial dysfunction, ROS production, and neuronal cell death. A shift in metabolism 
away from oxidative phosphorylation towards aerobic glycolysis has been shown to confer 
neuroprotection against A toxicity.  Hence, it was hypothesized that elevated TERT 
expression can protect neurons from mitochondrial dysfunction and Aβ toxicity via 
metabolic reprogramming. TERT overexpression in the neuronal cell line HT22 promoted a 
shift towards aerobic glycolysis by altering levels of glycolytic enzymes following exposure 
to H2O2 and Aβ. Furthermore, TERT overexpression decreased mitochondrial ROS levels 
and improved cell viability during oxidative stress.  Following exposure to H2O2 and Aβ, 
TERT translocation to the cytoplasm and mitochondria was observed. The results from this 
study suggest that TERT may be a therapeutic target for potential treatment of AD. 
Keywords 
telomerase reverse transcriptase, aerobic glycolysis, Warburg effect, metabolism, 
mitochondria, reactive oxygen species, oxidative stress, amyloid-beta, Alzheimer’s Disease 
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Chapter 1: Introduction and Literature Review 
1.1 Telomerase and TERT 
1.1.1 Telomerase and associated proteins  
Telomeres are specialized structures located on the ends of chromosomes that are 
comprised of double stranded guanine (G)-rich hexanucleotide tandem repeats 
(TTAGGG) followed by a single stranded TTAGGG overhang. The primary function of 
telomeres  is to prevent linear DNA from being recognized as a broken end, thereby 
preventing DNA end-to-end joining and DNA degradation1. However, DNA polymerases 
are unable to replicate the extreme ends of the 5’ strand during DNA replication resulting 
in a progressive loss of telomeres from chromosomes after each cell division.  This 
phenomenon is known as the end-replication problem2. Consequently, the shortening of 
telomeres to a  critical length, termed the Hayflick limit, leads to a loss of proliferation 
and initiation of cellular senescence3,4. Telomere attrition has been used as a biomarker 
for aging and is associated with many age-related diseases such as compromised immune 
function, various cancers, cardiovascular diseases and cognitive disorders4–6.   
Fortunately, telomere length can be preserved by the eukaryotic protein telomerase. 
Telomerase is a dimeric protein comprised of two main subunits; telomerase RNA 
component (TERC) and telomerase reverse transcriptase (TERT)7. Telomerase 
recognizes the hydroxyl group at the telomeric 3’ overhang and uses the TERC RNA 
template to catalytically add TTAGGG nucleotide repeats to telomeres7. In addition, the 
maintenance of telomeres relies on the shelterin complex which is required for the 
protection and stability of telomeres in a conserved T-loop configuration8. The shelterin 
complex is composed of six major subunits: telomeric repeat binding factor 1 and 2 
(TRF1, TRF2), TRF1-interacting nuclear factor 2 (TIN2), protection of telomeres protein 
1 (POT1), TPP1 and the human homolog of yeast RAP1 (RAP1)8. Telomere elongation is 
dependent upon the structure of the telomere itself. Longer telomeres attract more 
shelterin complexes which maintains the T-loop structure and enhances POT1 binding to 
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inhibit telomerase activity, while shorter telomeres surrounded by less shelterin are in a  
more open linear configuration that favours the recruitment of telomerase by TPP19. 
TERT expression and activity is high in cells undergoing extensive proliferation such as 
germ line cells of the testis, embryonic stem cells or malignant cancer cells10. In contrast, 
TERT is downregulated in most post-mitotic somatic cells11.  Expression of telomerase in 
adulthood is generally restricted to cells in highly regenerative tissues, such as 
lymphocytes in bone marrow and peripheral blood, epithelial cells in the skin, hair 
follicle, intestinal mucosa and endometrium, and adult stem cells12–16. 
1.1.2 Telomerase reverse transcriptase (TERT)  
Since the reactivation of TERT expression in somatic cells is a key step in cancer cell 
transformation, TERT is the most extensively studied telomere-associated protein. 
Human TERT (hTERT) is a 127kDa protein encoded by 1132 amino acids and consists 
of three main domains: the ~400 amino acid N-terminal region, a central region 
containing reverse transcriptase (RT) motifs and the ~200 amino acid C-terminal 
region17. The N-terminal region contains the highly conserved GQ motif which is 
essential for telomere maintenance, followed by a non-conserved linker sequence which 
is proposed to be important for nucleic acid binding, and conserved CP, QFP and T 
motifs responsible for binding to TERC18. The RT domain consists of 7 conserved motifs 
that contain three critical  aspartic acid residues needed for enzymatic activity, termed the 
catalytic triad, and regions needed for nuclease activity, nucleotide binding, rNTP/dNTP 
discrimination and nucleotide addition18. The C-terminal region is proposed to be 
involved in nucleotide addition and processivity18.  
1.1.3 Transcriptional/post-translational regulation of TERT 
Transcriptional regulation of TERT is important for determining a proliferative or post-
mitotic phenotype in cells. The ~14kb hTERT gene consists of 16 exons and 15 introns 
located on the small arm of chromosome 5 (5p15.33) as a single copy19. Although 
expression of full length  hTERT is required for telomerase activity, TERT mRNA can be 
alternatively spliced to generate α-TERT which contains a deletion in exon 6 and β-
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TERT which has a complete deletion of exon 7 and 820. The hTERT promoter is GC-rich 
with a CpG island 330 bp upstream of the ATG start codon21. The hTERT promoter 
contains specific domains for transcription factors that promote hTERT expression, such 
as two enhancer-boxes (E-boxes) for c-Myc/Myc associated factor X (Max) binding, five 
GC-boxes for binding of specificity protein 1 (Sp1) which cooperates with c-Myc, and 
estrogen response elements located more than ~950 bp upstream of the ATG22,23.  More 
importantly, transcriptional repression of hTERT can be regulated by the Max/Max 
associated protein D (Mad) complex which competitively binds to E-boxes22. Another 
transcriptional repressor of hTERT is the cell cycle arrest and tumor suppressor protein 
p53 which interacts with Sp1 to prevent binding to the hTERT promoter24. The 
transcription factor E2F-1 can bind to the promoter of hTERT to promote expression, 
however this effect can be abolished with the expression of retinoblastoma protein (pRB) 
which recruits histone deacetylases to promoter-bound E2F-125. Other repressors of 
hTERT transcription is the tumor suppressor Wilms’ tumor 1 (WT1) and myeloid-
specific zinc finger protein 2 (MZF-2)26,27. In addition, proteins involved in cell cycle 
arrest and differentiation can also inhibit hTERT expression such as interferon alpha 
(IFN-α) and transforming growth factor beta (TGF-β).  Moreover, certain naturally 
occurring or synthetic chemicals such as of vitamin D3, retinoic acid and dimethyl 
sulfoxide (DMSO) can repress hTERT expression28–31.   
Post translational regulation of hTERT occurs through protein interactions, 
phosphorylation, and ubiquitination. The p23 foldasome chaperone binds to the N-
terminal region of hTERT and recruits heat shock protein 90 (Hsp90), both of which are 
required for assembly of active telomerase with TERC and are the only proteins that 
remain associated with active telomerase after assembly32. In addition, human homologs 
of the yeast essential telomerase proteins (EST), hEST1A and hEST1B, can bind to 
hTERT and contribute to telomere maintenance and protection33.  Other proteins shown 
to bind to hTERT to enhance telomerase activity are the DNA-PKC interacting protein 
KIP which can bind to amino acids 762-855, and Ku which links hTERT with TRF1 and 
TRF234,35. A negative regulator of telomerase is the nucleolar TRF1- binding protein 
PinX1, which binds to and sequesters hTERT  thereby inhibiting interaction with TERC 
and  preventing activation36. While phosphorylation of hTERT at the N-terminal region 
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by proteins such as the alpha isoform of protein kinase C (PKCα) contributes to active 
telomerase, phosphorylation by Abelson murine leukemia viral oncoprotein (c-Abl), 
phosphatase 2A, and PKCζ proteins inhibit telomerase activity37. The ubiquitin ligase 
Makorin Ring Finger Protein 1 (MKRN1) has also been reported to associate with the C-
terminal region of hTERT to promote degradation38. Other ubiquitin ligases that can 
negatively regulate TERT activity is C terminus of HSC70-Interacting Protein (CHIP) 
and Hdm2 (E3 Ligase)39,40. 
1.1.4 TERT expression in the brain 
TERT activity is generally limited by its restricted expression and is generally 
downregulated in most post-mitotic cells. However, TERT has unusual expression 
patterns in the brain, irrespective of telomerase activity. Telomerase activity is high 
during embryonic and early postnatal development, but declines shortly thereafter and is 
undetectable in adult brains41,42. When mouse brain extracts corresponding to the cortex, 
hippocampus, and brain stem were examined, telomerase activity peaked in all regions at 
embryonic day 13 (E13), declined to low levels by E18, and was undetectable by 
postnatal day 10 (P10)43. In contrast, high TERT mRNA levels persist until P5 and low 
levels can be detected in the same regions of the adult brain43. By E18 the hippocampus 
contains fully differentiated post mitotic neurons and upon further analysis, it was found 
that TERT is expressed primarily in hippocampal pyramidal neurons and cortical neurons 
but not in astrocytes.  In addition, experiments in which TERT expression was either 
increased or decreased demonstrated that the protein plays a pivotal role in suppressing 
apoptosis induced by trophic factor withdrawal well before mitochondrial dysfunction or 
caspase activation44.  Since access to trophic factors determines neuronal survival during 
development, it has been  proposed that TERT regulates synaptic pruning and neuronal 
differentiation during early postnatal brain development43,44.   
In the adult brain, telomerase activity can be detected in areas with high proliferation, 
such as the subventricular zone of the lateral ventricle, a region which contains neural 
stem cells45.  In addition, TERT expression has been detected in the dentate gyrus of the 
hippocampus and the glomeruli, mitral/tufted cell layer, and the olfactory granule cell 
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layer of the olfactory bulb, independent of TERC expression46. Interestingly, TERT may 
be important for regulating normal brain functions since TERT knock out mice display 
altered anxiety-like behaviours and abnormal olfaction46. TERT has also been detected in 
the cerebellum, specifically in the nucleus and cytoplasm of Purkinje neurons in adult and 
old mice47. 
1.2 Non-canonical functions of TERT 
1.2.1 Non-canonical functions of TERT in the nucleus 
Several studies have suggested that TERT may have functions independent of telomere 
extension. TERT overexpression has been reported to promote tumorigenesis by 
influencing the expression of genes involved in cell growth and proliferation, 
independent of telomere elongation48. Furthermore, downregulating TERT expression 
dramatically increases apoptotic cell death well before detectable telomere shortening49. 
Studies in TERT-deficient mouse models have revealed that TERT can regulate survival, 
tumorigenesis, stem cell properties and gene regulation independent of changes in 
telomere length50,51. TERT may also play a critical role in maintaining healthy 
mitochondria, as restricting TERT localization exclusively to the nucleus increases 
telomeric and extra-telomeric DNA damage, reactive oxygen species (ROS) production 
and mitochondrial dysfunction52.  
Apart from TERT’s canonical function as a subunit in telomerase, non-canonical 
functions of TERT within the nucleus have been reported. Nuclear import of TERT is 
dependent on a bipartite nuclear localization signal residing within amino acid residues 
222-240 and by phosphorylation on serine 227 by the Akt serine/threonine kinase53. 
Another mechanism of nuclear import is through the interaction of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) with TERT in the cytosol, which is 
recognized by tumor necrosis factor alpha (TNFα) leading to nuclear translocation54. In 
the nucleus, NF-κB can induce TERT expression which can then act as a transcriptional 
modulator in the NF-κB signaling pathway by binding to p65 and p50 to influence 
transcription of NF-κB target genes regulating inflammation and cancer progression55,56. 
TERT is also known to bind to the SWI/SNF-related chromatin remodelling protein 
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BGR1 to regulate genes involved in proliferation and stem cell renewal via the Wnt/β-
catenin signalling pathway57. In addition, TERT may be responsible for the maintenance 
of chromatin structure and plays a role in the response to DNA double strand breaks58,59. 
Moreover, TERT may participate in telomere capping to stabilize telomeres and increase 
lifespan, independent of telomere lengthening60,61. 
1.2.2 Properties and functions of mitochondria 
Surprisingly, many non-canonical functions of TERT have been reported as a result of its 
mitochondrial localization. The mitochondria are cytoplasmic organelles that play a vital 
role in maintaining cellular homeostasis and energy production. The structure of this 
organelle consists of the mitochondrial matrix surrounded by the inner mitochondrial 
membrane (IMM) organized in the form of folds or cristae. The IMM is separated from 
the outer mitochondrial membrane (OMM) by the intermembrane space. The 
mitochondria has key functions in producing adenosine triphosphate (ATP) and ROS, 
initiating apoptosis by releasing proteins that activate caspases, and controlling 
intracellular calcium concentrations62.  
Also termed the “powerhouse” of the cell, the mitochondria are essential for producing 
ATP via oxidative phosphorylation (OXPHOS) to meet cellular energy demands. After 
glucose enters the cell via GLUT transporters, it is metabolized to pyruvate through a 
series of enzyme catalyzed reactions collectively terms glycolysis63. Pyruvate is actively 
shuttled to the mitochondria through mitochondrial pyruvate carriers (MPC), where it is 
converted to acetyl coenzyme A (acetyl-CoA) by the enzyme pyruvate dehydrogenase 
(PDH) to act as the first substrate within the citric acid cycle (TCA)63. The high-energy 
reduced products from the TCA, nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2), are subsequently oxidized in the electron transport chain 
(ETC), consisting of five complexes named I-V that are located in the IMM63. The 
transfer of electrons through complexes I-V transports protons across the IMM to the 
intermembrane space, resulting in a membrane potential across the IMM. The 
electrochemical proton gradient across the IMM drives protons back into the matrix 
through complex V (ATP synthase), which uses that energy to convert adenosine 
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diphosphate (ADP) to ATP63.  The entire process produces a net of 34 ATP molecules per 
oxidation of one glucose molecule compared to a net of 2 ATP molecules per glucose 
molecule produced during glycolysis63. However, complexes I-III can sometimes leak 
electrons resulting in the production of oxygen radicals such as superoxide (O2
-), 
hydroxyl radical (OH-) and hydrogen peroxide (H2O2)
64. Low levels of ROS may be 
beneficial to the cell, as ROS can be used as a signalling molecule that initiates signalling 
cascades important for the redox balance of a cell. Conversely, excessive ROS can lead to 
oxidative stress characterized by damage to cell structures, DNA, lipids and proteins65. 
Levels of intracellular ROS can be controlled by a variety of antioxidant enzymes such as 
catalase, superoxide dismutase (SOD), and glutathione peroxidase (GPx)66. 
The mitochondria also play a key role in initiating cell death via the intrinsic apoptosis 
pathway. Apoptosis is regulated by the activation of a family of cytosolic caspase 
proteases, which cleave cellular contents to initiate programmed cell death67. The 
intrinsic pathway of apoptosis relies heavily on mitochondrial components and the 
release of cytochrome C, which is a part of the apoptosome complex and can initiate the 
activation of caspases68. The anti-apoptotic B-cell lymphoma 2 (Bcl-2) proteins reside in 
the OMM and maintain mitochondrial outer membrane permeability (MOMP) to block 
cytochrome C release69. However, pro-apoptotic proteins such as Bcl-2-associated X 
protein (Bax), which is a subset of proteins from the Bcl-2 family, can translocate from 
the cytosol to the mitochondria, undergo oligomerization thereby promoting changes in 
MOMP to release cytochrome C from the intermembrane space to the cytosol69. The 
translocation of Bax to the mitochondria is considered a key upstream initiator of 
intrinsic apoptosis69. 
Calcium regulation is another important function of the mitochondria.  Calcium acts as a 
signalling molecule that has spatially and temporally complex functions, some of which 
include roles in metabolism, secretion, muscle contraction, gene expression, and 
proliferation70.   Typically, the cytosol maintains a very low concentration of Ca2+ with 
the aid of Ca2+ pumps and transporters70. The mitochondria can act as a buffer and 
respond to Ca2+ influx to the cytosol by providing the rapid removal and storage by 
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uptake of excess Ca2+ 70. In neurons, calcium signalling plays a vital role in signal 
transmission, excitability, and synaptic plasticity70. 
1.2.3 TERT localizes to the mitochondria under oxidative stress 
Under normal conditions, approximately 10-20% of the total cellular TERT is localized 
to the mitochondria71. However, oxidative stress has been shown to trigger increased 
TERT accumulation in the mitochondria; an event linked to mitigation of mitochondrial 
dysfunction72,73.  Nuclear exclusion occurs in as little as 45 mins after oxidative stress 
treatment, reaching a maximum exclusion level of 60% after 24 hours and can persist up 
to 5 days, depending on the cell type74. TERT phosphorylation on tyrosine 707 by the 
proto-oncogene Src kinase triggers nuclear export by promoting association with GTP-
binding nuclear protein Ras-related nuclear protein (Ran GTPase) and the nuclear export 
receptor chromosomal maintenance 1/exportin 1 (CRM1/XPO1)75. Alternatively, nuclear 
export of TERT can be negatively regulated by the protein tyrosine phosphatase Shp-2, 
which is known to antagonize the activities of the Src kinase family76,77. Nuclear export 
can also be inhibited by the 14-3-3 signaling protein which interferes with CRM1/XPO1 
binding to the nuclear export signal located at the C-terminus of TERT78. After successful 
nuclear export, cytosolic TERT is directed to the mitochondria via a mitochondrial 
targeting sequence (MTS), which is encoded within the first 20 amino acids79. TERT 
interacts with mitochondrial transport protein complexes translocases of the outer 
membrane 20/40 (TOM 20/40) and translocase of the inner membrane (TIM23) to cross 
the mitochondrial membranes and enter the mitochondrial matrix80,81. 
1.2.4 TERT has catalytic activity in the mitochondria 
In the mitochondria, TERT can have reverse transcriptase activity even in the absence of 
TERC. TERT interacts with mitochondrial tRNAs to synthesize cDNA, suggesting a role 
in mitochondrial DNA (mtDNA) replication or repair71.  Conversely, TERT has been 
shown to have a novel RNA-dependent RNA polymerase (RdRP) activity that is 
independent of its DNA reverse transcriptase function, and is the only RdRP identified in 
mammals82.  TERT forms a complex with the mitochondrial RNA processing 
endoribonulease (RMRP) and is able to produce siRNAs from double-stranded RNAs, 
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which can influence transcriptional or post-transcriptional gene silencing of the RMRP 
gene82.   
1.2.5 TERT prevents mitochondrial dysfunction under oxidative stress conditions 
Recent studies have demonstrated that mitochondrial localization of TERT contributes to 
the proliferative and survival properties of cancer cells79,83. Under oxidative stress 
conditions, TERT prevents mtDNA oxidative damage and degradation, decreases 
mitochondrial superoxide production and ROS levels and maintains a high mitochondrial 
membrane potential73,74,77,80,81. These effects on mitochondrial function may indirectly 
protect against nuclear DNA damage and apoptosis in response to oxidative stress74,80. A 
possible mechanism for TERT-mediated reduction in ROS production and suppression of 
apoptosis is by decreasing ROS-induced cytosolic acidification and blocking 
translocation of Bax to the mitochondria, which is critical for pro-apoptotic signalling81. 
TERT plays a central role in cell viability through regulation of intrinsic mitochondrial-
induced apoptosis, which makes it an attractive target for cancer therapeutics84.  While 
some studies have shown that TERT catalytic activity in conjunction with TERC 
expression may be essential for suppression of apoptosis, overexpression of an 
catalytically inactive form of TERT has been shown to inhibit Bcl-2 and p53 dependent 
apoptosis85–87. In addition, TERT inhibition via siRNA sensitizes cells to the activation of 
Bax and subsequent apoptosis88. Downregulation of TERT results in activation of the 
JNK/p38-MAPK pathway and increased cleavage of  caspase 3, 8 and 9, which are 
involved in mitochondrial induced apoptosis89,90.  Downregulation of TERT is also 
associated with an increase of cytosolic cytochrome C due to disrupted mitochondrial 
membrane potential91.  
TERT overexpression reduces basal ROS levels and overall ROS production during 
oxidative stress conditions81.  This may be accomplished through improving respiratory 
chain activity or antioxidant activity. Mitochondrial TERT reduces succinate-linked 
respiration and decreases complex I activity, both of which contribute to mitochondrial 
ROS production80. TERT can bind to mtDNA at coding sequences for NADH:ubiquinone 
oxidoreductase (complex I) subunit 1 and 2 (ND1 and ND2), which is thought to increase 
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synthesis of these subunits and allow for replacement of subunits damaged by ROS 
production80.  Furthermore, TERT overexpressing cells improve mitochondrial function 
by limiting levels of the uncoupling protein uncoupling protein 2 (UCP2), which is 
transcriptionally upregulated by high ROS levels73. TERT can also affect the production 
and availability of various antioxidants to reduce ROS production. TERT overexpressing 
cells have a higher reduced glutathione compared to oxidized glutathione, which is an 
important co-factor for GPx activity81. It was also observed that TERT overexpressing 
cells upregulate glutamate cysteine ligase (GCL), the enzyme needed for the production 
of glutathione and exhibit a more rapid recovery of peroxiredoxin isoforms from their 
hyperoxidized state81. Moreover, TERT overexpressing cells exhibit increased complex 
IV activity, which contributes to the electrochemical proton gradient utilized by ATP 
synthase (complex V) for ATP production81. 
1.2.6 Mitochondrial localization of TERT is neuroprotective 
Mitochondrial localization of TERT may also benefit neurons due to its anti-apoptotic 
functions, implicating a vital role in aging and neurodegenerative disease. Specifically in 
brain tissue, dietary restriction or inhibitors of the mechanistic target of rapamycin 
(mTOR) pathway decreases ROS production, but this is dependent on an increase of 
TERT transcription and protein localization to the mitochondria92.  In cerebellar Purkinje 
neurons, neuronal stressors such as glutamate excitotoxicity increases mitochondrial 
TERT localization93.  
Primary neuronal cultures derived from transgenic mice overexpressing TERT have 
increased neuronal survival following N-methyl-D-aspartate (NMDA) exposure 
compared to neuronal cultures from control mice94–96.  This increase in cell survival may 
occur due to TERT mediated effects on mitochondrial membrane potential and 
mitochondrial uptake of Ca2+, thereby decreasing the accumulation of cytosolic free 
calcium Ca2+ after NMDA receptor activation94. In addition, TERT was detected in the 
cytosol and nucleus of microglia up to 7 days after excessive stimulation of NMDA 
receptors by the seizure-inducing drug kainite97. 
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TERT is also protective against initiators of apoptosis in neurons following exposure to 
various forms of stress. TERT inhibition in cultured neurons that are deprived of oxygen 
and glucose results in increased caspase 3 cleavage, decreased Bcl-2/Bax expression, 
enhanced ROS production, and reduced mitochondrial membrane potential98. In a 
transgenic mouse model of amyotrophic lateral sclerosis (ALS), increased TERT 
expression protected against spinal cord motor neuron death96. Neuroprotection is 
believed to be mediated, in part, by tropomyosin receptor kinase B (TrkB) induced 
signalling of brain derived neurotrophic factor (BDNF) which can upregulate 
transcription factors c-Myc, Sp1 and NF-κB, thereby increasing TERT expression and 
telomerase activity in spinal cord motor neurons undergoing injury99.  This confers 
resistance to apoptosis mediated through Bcl-2, Bax, p53 and a maintenance of 
mitochondrial membrane potential99. Another study has shown that in hippocampal 
neurons, TERT localizes to cytosolic RNA granules100.  Within the RNA granules, TERT 
colocalizes with p15INK4B mRNA, which is known to promote cell cycle arrest by 
inhibition  of cyclin-dependent kinases CDK4 and CDK6100. Upon acute stress, TERT 
disassociates from the P15INK4B mRNA allowing for translation, suggesting this may be 
a mechanism for TERT’s pro-survival effect in neurons100.   
There is also evidence that TERT may contribute to the protective roles in cell types 
other than neurons in the brain after tissue injury. After permanent ischemic damage, 
TERT mRNA is rapidly increased within 4 hours in the cytoplasm of surviving ipsilateral 
cortical neurons94.  However, a separate study showed that TERT protein expression 
shifts from neurons to astrocytes after 3 days in a hypoxic-ischemic rat model101. 
Transient ischemic brain injury also induced increased TERT mRNA expression in 
astrocytes in the uninjured ipsilateral hemisphere102.  TERT expression in astrocytes 
corresponds with an upregulation of the cell cycle regulator p15 to inhibit proliferation of 
reactive astrocytes and the increased expression of neural growth factor neurotrophin-3 
(NT-3) to promote neuronal survival101.  
1.3 Alzheimer’s Disease and TERT 
1.3.1 Alzheimer’s Disease and oxidative stress 
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Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide. It is 
characterized by the deposition of intracellular neurofibrillary tangles composed of 
hyper-phosphorylated tau protein and extracellular plaques composed of amyloid-beta 
(Aβ) peptides103. Early-onset AD occurs in 1%-6% of cases and is most commonly the 
result of a mutation in the amyloid precursor protein (APP) or the secretases (PSEN1, 
PSEN2) that shift the processing of the APP to the pathogenic 1-42 amino acid Aβ 
peptide (Aβ1-42)104. This Aβ1-42 peptide can spontaneously aggregate into soluble 
oligomers, and further accumulate to form insoluble beta-sheet fibrils, finally forming 
deposits of diffuse or compact plaques105. Over time, there is progressive degeneration of 
neurons and synapses in areas of the brain involved in memory and cognition such as the 
hippocampus, entorhinal cortex, and basal forebrain106. 
Mitochondrial dysfunction and oxidative stress are prominent features of many 
neurodegenerative diseases107. A neuron’s high energy demand makes it reliant on 
mitochondrial oxidative phosphorylation to produce ATP, which is more efficient at ATP 
production than glycolysis108. However, due to the high number of neuronal mitochondria 
and the relatively low levels of antioxidant enzymes compared to other organs, neurons 
are especially vulnerable to ROS109. Aging can lead to increased mitochondrial DNA 
mutations and damaged complexes in the ETC, leading to elevated electron leakage and 
reduced ATP synthesis63. It has also been reported that patients with AD have altered 
mitochondrial morphology, reduced cytochrome c oxidase (complex IV) activity and 
reduced activity of enzymes within the TCA cycle62,110. In addition, glycolysis is 
perturbed as evidenced by lower levels of glucose transporters (GLUT1 and GLUT3) and 
enzymes involved in glycolysis (phosphofructokinase (PFK), glucose6-phosphate 
isomerase and lactate dehydrogenase in the brains of AD patients compared to age 
matched controls111,112. A decrease in glucose consumption and oxygen metabolic rates 
are observed during normal aging, but this effect is further exacerbated during 
neurodegenerative disease, such as AD113. 
In AD, oxidative damage occurs well before Aβ plaque accumulation and is believed to 
be a major contributor to pathogenesis114. Recent studies suggest that neuronal 
dysfunction and degeneration is due to the accumulation of intracellular Aβ, which 
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eventually causes lysis of the cell leading to extracellular Aβ plaque deposition115,116. The 
Aβ1-42 oligomers have been shown to be toxic to neurons, synapses and the mitochondria 
by promoting ROS production, oxidative damage, and  tau phosphorylation117,118. Aβ1-42 
oligomers directly interfere with mitochondrial function via Aβ binding alcohol 
dehydrogenase (ABAD) resulting in mitochondrial impairment, ROS production, and cell 
death119. In addition, transgenic mice that express mutant human APP reveal decreased 
basal levels of mitochondrial membrane potential at 3 months of age compared to 
littermate controls109. At this time, only moderately elevated intracellular Aβ load is 
detected, suggesting that Aβ production interferes with mitochondrial function well 
before Aβ plaque deposition109. Since current insights of AD pathology propose there is a 
cyclic relationship between oxidative damage and Aβ production, it may be useful to 
investigate targets that reduce the damaging effects of oxidative stress62. Recently, it has 
been proposed that lifestyle factors such as dietary restriction, intellectual activity and 
exercise may target intrinsic biological mechanisms to limit oxidative damage120,121. 
Surprisingly, amyloid-deposition is observed in about 25% of cognitively normal elderly 
individuals122. Investigation of Aβ resistant cells reveal an upregulation of antioxidant 
enzymes such as peroxiredoxin 1 (Prx1), GPx and catalase. In addition, Aβ resistant cells 
exhibit an increase in glucose uptake and glycolysis due to an activation of transcription 
factor hypoxia inducible factor 1 (HIF-1)123–125. Increased activation of the alpha subunit 
of HIF-1 (HIF-1α) is frequently observed in tumors resulting in an increase of glucose 
uptake and lactate production, even in the presence of oxygen126. This phenotype is 
termed the Warburg effect or aerobic glycolysis. In vitro studies of Aβ resistant cells 
demonstrate that elevated aerobic glycolysis is a neuroprotective mechanism that 
decreases mitochondrial ROS production and increases resistance to Aβ -induced 
apoptosis127. Furthermore, increased expression of rate-limiting enzymes in aerobic 
glycolysis, such as lactate dehydrogenase (LDHA) or pyruvate dehydrogenase kinase 1 
(PDK1), can protect against Aβ toxicity128. Positron emission tomography (PET) imaging 
of AD patients demonstrated that aerobic glycolysis correlates spatially in individuals 
that have high Aβ plaque deposition but are cognitively normal129. Altogether, these 
results suggest that neurons may become resistant to the toxic effects of Aβ by altering 
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their metabolism, moving away from OXPHOS and towards aerobic glycolysis for their 
energy needs. 
1.3.2 TERT is protective against amyloid-beta 
Telomere shortening and a decrease in TERT expression occurs significantly more in 
hippocampal neurons of AD patients compared to aged matched controls130. Recent in 
vitro studies demonstrate that increasing TERT expression and activity may be beneficial 
against Aβ toxicity. One study showed that estrogen receptor activation is 
neuroprotective against Aβ toxicity in a manner dependent on upregulation of TERT 
activity131. A proposed mechanism is through activation of TERT via phosphorylation by 
Akt kinase, causing TERT to associate with NF-κB and translocate to the nucleus where 
telomerase activity can occur131. A separate study determined that treating primary 
murine cerebrovascular endothelial cells with calf serum was able to reverse Aβ-
inhibition of HSP90 expression, a protein which binds to TERT, and facilitate an 
upregulation of telomerase activity to prevent apoptosis induced by Aβ132. Similarly, 
TERT may protect mouse hippocampal neurons from Aβ induced apoptosis by limiting 
mitochondrial ROS production and by maintaining mitochondrial membrane potential133. 
Interestingly, the vaccine peptide GV1001 derived from the TERT sequence blocks Aβ 
toxicity by localizing to the mitochondria of rat neural stem cells and reduces ROS levels, 
mitochondrial DNA damage, and alters expression levels of survival/death related 
proteins to prevent apoptosis134. More recently, in vivo studies in mice have confirmed 
that while TERT is expressed in both aged control and transgenic AD adult hippocampal 
neurons, the organelle localization of TERT differed between these two groups132. 
Mitochondrial localization of TERT was observed in transgenic AD brains and the 
presence of TERT was mutually exclusive from hyper-phosphorylated tau, suggesting a 
neuroprotective function against tau pathology135. 
1.4 Rationale  
The current field of research has recognized many physiological functions of TERT apart 
from its canonical role in maintaining telomeres. Most importantly, it has been shown 
that mitochondrial localized TERT protects against oxidative stress and the toxic effects 
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of the Aβ, a peptide strongly implicated in AD pathogenesis. In addition, Aβ resistant 
cells have been known to switch their metabolism to aerobic glycolysis through a 
mechanism which is poorly defined. I hypothesize that TERT will localize to the 
mitochondria and alters metabolism in a manner which renders neurons less 
susceptible to toxicity following exposure to Aβ or oxidants. As a result of 
mitochondrial localization of TERT, mitochondrial ROS levels will lower and cell 
viability will increase in Aβ challenged cells. Since mitochondrial dysfunction is a 
prominent feature of AD, the discovery of mitochondrial associated functions of TERT 
may implicate TERT as a potential therapeutic target for AD and other neurodegenerative 
diseases. 
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Chapter 2: Materials and Methods 
2.1 Plasmids 
Human TERT (072-hTERT, referred to as TERT) and 071-FLAG-hTERT (referred to as 
FLAG-TERT) cDNA expression plasmids were generously provided by Dr. Lea 
Harrington (IRIC, Montreal, Quebec, Canada). The pcDNA 3.1 plasmid (referred to as 
pcDNA; Invitrogen) was used as a transfection control in all experiments. The pcDNA3-
EGFP plasmid (referred to as GFP; Addgene) was used as a transfection control for 
MitoTracker CMXROS experiments. Transfection efficiency was between 40-50%, 
which was assessed following co-transfection of the TERT plasmid with GFP and 
visualization by fluorescence microscopy. 
2.2 Cell Culture 
The HT22 immortalized mouse hippocampal neuronal cell line was a gift from Dr. Dave 
Schubert (Salk Institute for Biological Sciences, California, USA). HT22 cell cultures 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza) 
supplemented with 10% Fetal Bovine Serum (FBS) (Corning) and 1% 
penicillin/streptomycin (P/S) (Gibco). Cells were cultured in an incubator at 37°C and 
5% CO2. 
2.3 Aβ Preparation 
Aβ(25-35) was purchased from California Peptide and dissolved in sterile ddH2O to a 
concentration of 1 mM then left overnight at room temperature to allow fibril formation 
before storing at -20°C, as previously described127.   
2.4 Western Blot 
HT22 cells were seeded at 150 000 cells per 60 mm cell culture dish and grown to 50%-
70% confluency then transfected with 3 µg DNA (TERT, pcDNA) using 1 mL Opti-
MEM (Gibco) and 5 µL Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instructions. Transfection media was replaced with DMEM + 10% FBS + 1% P/S media 
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after 5 hours and the cell cultures recovered overnight.  The following day cell cultures 
were treated for 4 hours with 400 µM H2O2 (Sigma) or 25 µM Aβ25-35 (California 
Peptide),then washed twice in Phosphate Buffer Saline (PBS; Lonza) and lysed in ice-
cold RIPA buffer (10 mM Tris-Hcl pH 8, 1% Triton X-100 (Sigma), 0.1% Sodium 
deoxycholate, 0.5 mM EGTA, 0.1% SDS, 140 mM NaCl) containing a protease inhibitor 
cocktail (2 mM leupeptin (Sigma), 0.1 mM pepstatin A (Sigma)), phenolmethanesulfonyl 
fluoride (Sigma), and sodium orthovanadate (Sigma). Protein content from whole cell 
lysate was quantified using the DC protein assay (Bio-Rad). Protein samples were 
resolved by 10% SDS-PAGE, immunoblotted onto polyvinylidene fluoride membrane 
(Bio-Rad), and blocked in TBS-T buffer containing 3% BSA (VWR), 1% non-fat dry 
milk (Cell Signalling). Blots were hybridized with the following primary antibodies: anti-
hTERT (600-401-252S; Rockland), anti-PDH (ab110334; abcam), anti-Actin (sc-47778; 
Santa Cruz), anti-pser232 PDH (AP1063; EMD Millipore), anti-LDHA (#2012; Cell 
Signalling), anti-PDK1 (ADI-KAP-PK112-F; Enzo Life Sciences), anti-PKM1 (#7067; 
Cell Signalling), and anti-PKM2 (#3198; Cell Signalling). Following incubation with 
HRP-conjugated secondary mouse (sc-2005; Santa Cruz) and rabbit (sc-2030; Santa 
Cruz) antibodies, blots were visualized by enhanced chemiluminescence using the 
Luminata Forte substrate (EMD Millipore) and imaged in a Chemidoc XRS System (Bio-
Rad). Densitometric quantification of band intensity of three independent experiments 
was performed using Image Lab software (Bio-Rad). 
2.5 MitoTracker Red CMXROS 
To determine mitochondrial ROS levels of the cells, the fluorescent dye MitoTracker Red 
CMXRos (Life Technologies) was used. HT22 cells were seeded at 80, 000 cells per 35 
mm cell culture dish and grown to 50%-70% confluency.  The cell cultures were 
transfected with 1.2 µg DNA (TERT/pcDNA:GFP, 2:1 ratio) and 2 µL Lipofectamine 
2000 in 800 µL Opti-MEM according to manufacturer’s instructions. Transfection media 
was replaced with DMEM + 10% FBS + 1% P/S media after 5 hours.  The following day, 
cell cultures were treated for 12 hours with 400 µM H2O2 or 25 µM Aβ25-35. After 
treatment, the cell cultures were incubated at 37°C for 20 minutes with phenol-red free 
DMEM + 10% FBS + 1% P/S containing 200 nM MitoTracker Red CMXRos. Cells were 
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washed twice with PBS and incubated with 10 ug/mL Hoeschst (Life Technologies) in 
PBS for 1 minute at room temperature. Cells were rinsed with PBS, placed in phenol-red 
free DMEM + 10% FBS + 1% P/S and analyzed by fluorescence microscopy using a 
Leica DMI6000 B microscope equipped with an ORCA Hamamatsu digital camera. All 
digital images were captured at the same exposure time and analyzed using ImageJ 
software (National Institute of Health). The mean red fluorescence of three images per 
treatment was calculated for each of three independent experiments. 
2.6 Cell Viability Assay 
The MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay was 
used to assess cell viability. 150 000 HT22 cells were seeded in a 60 mm cell culture dish 
and grown to 50%-70% confluency. Cell cultures were transfected with 3 µg DNA 
(TERT, pcDNA) and 5 µL Lipofectamine 2000 in 1 mL Opti-MEM according to 
manufacturer’s directions. Transfection media was replaced with DMEM + 10% FBS + 
1% P/S media after 5 hours and the next morning, cells were trypsinized and 7 000 cells 
per well were seeded in a 96-well plate with DMEM + 10% FBS + 1% P/S media. After 
cell adherence (approx. 5 hours), the cells were treated for 24 hours with DMEM + 5% 
FBS + 1% P/S media containing 400 µM H2O2 or 25 µM Aβ25-35. The concentration of 
Aβ was chosen based on previous studies127 whereas the H2O2 concentration was 
determined following a dose response curve (see Appendix 5).  Live cells were visualized 
and representative images were taken for each treatment using a Leica DMIL LED phase 
contract microscope. Then the media was replaced with DMEM + 5% FBS + 1% P/S 
media with MTT reagent (Sigma) added at a final concentration of 10%. Culture plates 
were incubated at 37°C for 3 hours. After incubation, culture medium containing MTT 
was aspirated, replaced with DMSO and the optical density was measured at 595 nm 
using a microplate reader (Bio-Rad Model 3550). All treatments were seeded in 
triplicates and the mean viability was calculated from three independent experiments. 
2.7 Immunofluorescence 
Cover slips were placed in a 6-well plate and treated with 50 µg/mL Poly-D lysine 
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(Sigma) overnight. After washing with sterile water, 60 000 HT22 cells per well were 
seeded and grown to 50% confluency. Cell cultures were transfected with 1.2 µg DNA 
(FLAG-TERT, pcDNA) 2 µL Lipofectamine 2000 (Invitrogen) in 800 µL Opti-MEM 
according to manufacturer’s instructions. Transfection media was replaced with DMEM 
+ 10% FBS + 1% P/S media after 5 hours and the next morning, cells were treated for 12 
hours with 400 µM H2O2 or 25 µM Aβ25-35. Cells that adhered onto cover slips were 
transferred to a 12-well cell culture plate, washed twice with PBS and fixed with ice cold 
4% paraformaldehyde in PBS for 10 minutes at room temperature. Cells were washed 
once with PBS and then twice with PBS + 1% Triton X-100 before blocking with 3% 
goat serum (Invitrogen) in PBS + 1% Triton-X-100 for 1 hour at room temperature. Fixed 
cells were hybridized with the primary antibodies anti-FLAG (F3165; Sigma) and anti-
TOM20 (sc-11415; Santa Cruz) diluted 1:200 in in 3% goat serum in PBS + 1% Triton-
X. Following an overnight incubation at 4°C, coverslips were washed twice with PBS + 
1% Triton-X followed by hybridization with anti-mouse IgG secondary antibody 
conjugated to Alexa Fluor 488 (Invitrogen) and goat anti-rabbit IgG secondary antibody, 
Alexa Fluor 594 (Invitrogen) diluted 1:200 in 3% goat serum in PBS + 1% Triton-X for 1 
hour at room temperature. Cover slips were then washed twice with PBS + 1% Triton-X 
and then mounted on a glass slide using ProLong Gold Antifade Mountant with DAPI 
(Invitrogen). Clear nail polish was used to seal the edges. Slides were visualized by 
fluorescence microscopy using the Leica DMI6000 B equipped with an ORCA 
Hamamatsu digital camera. Images were captured at the same exposure time for all 
treatments. 
2.8 Statistical Analysis 
Data are presented as means ± SD resulting from three independent experiments. Data 
were analyzed statistically using a one-way ANOVA followed by a Tukey test (GraphPad 
software). Results were considered statistically significant at p≤0.05. 
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Chapter 3: Results 
3.1 TERT partially localizes with mitochondria following H2O2 or 
Aβ exposure  
Previous studies have shown that TERT localizes to mitochondria under oxidative 
conditions136–138 . Due to low expression of endogenous TERT and the lack of anti-TERT 
antibodies suitable for immunofluorescence staining, HT22 cells were transfected with a 
FLAG-TERT plasmid to allow the use of an anti-FLAG antibody to detect overexpressed 
TERT. Cells were then treated with 400 µM H2O2 and 25 µM Aβ25-35 for 12 hours and 
co-staining was performed using anti-FLAG and anti-TOM20 (mitochondrial marker) 
antibodies. DAPI was used as a nuclear marker. Under control conditions, TERT 
expression is primarily nuclear, as illustrated by colocalization of FLAG (green) with 
DAPI (blue) (Figure 1A). However, after 12 hours of oxidative stress induced by 400 µM 
H2O2 and 25 µM Aβ25-35 exposure, there are two patterns of TERT localization that 
emerge (Figure 1B,C). The first is characterized by reduced localization of TERT from 
the nucleus and increased localization to mitochondria. The second pattern shows TERT 
is present in both the nucleus and the mitochondria. Both patterns illustrate that TERT 
may have non-canonical mitochondrial functions under oxidative stress conditions. 
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3.2 TERT expression promotes a shift towards glycolysis under 
oxidative stress  
To assess the effect of TERT expression on metabolic enzyme levels, HT22 cells were 
transfected with TERT or pcDNA plasmids, followed by a 4 hour exposure to low and 
high concentrations of H2O2 (100 µM, 400 µM) and 25 µM Aβ25-35. No toxicity was 
observed following a four hour exposure to these stressors (data not shown). Protein 
levels of enzymes involved in metabolism were assessed via Western blotting (Figure 
2A). Pyruvate dehydrogenase (PDH) is the rate-limiting enzyme that catalyzes the 
conversion of pyruvate to acetyl-CoA to fuel the TCA cycle. Increased phosphorylation 
of PDH at serine 232 by pyruvate dehydrogenase kinase 1 (PDK1) restricts OXPHOS by 
rendering PDH inactive, resulting in a metabolic shift towards glycolysis to satisfy the 
cell’s energy requirements. TERT transfected cells had elevated levels of phospho-
PDH/total PDH and PDK1 when stressed with 100 µM H2O2, 400 µM H2O2 and 25 µM 
Aβ25-35 (Figure 2B), indicative of less OXPHOS. Another important enzyme involved in 
glycolytic metabolism is lactate dehydrogenase A (LDHA). LDHA catalyzes the 
conversion of pyruvate to L-lactate while oxidizing NADH to NAD+ as a by-product. 
TERT transfected cells had elevated levels of LDHA when stressed with 100 µM H2O2, 
400 µM H2O2 and 25 µM Aβ25-35 (Figure 2B), indicative of enhanced glycolytic 
metabolism. Finally, the levels of alternatively spliced M1 and M2 isoforms of pyruvate 
kinase (PK) were quantified. PK catalyzes the irreversible reaction between 
phosphoenolpyruvate (PEP) and ADP to produce pyruvate and ATP in the last step of 
glycolysis. While PKM1 is constitutively active, the dimeric form of PKM2 is expressed 
in tissues with high anabolic functions, such as cancer cells, and has a low affinity for 
PEP139. This results in the accumulation of glycolytic intermediates, which enter the 
glycerol synthesis and pentose phosphate pathways (PPP), limiting the production of 
pyruvate to fuel OXPHOS139. A decrease in the ratio of PKM1/PKM2 enzymes was 
observed in TERT transfected cells when stressed with 100 µM H2O2, 400 µM H2O2 and 
25 µM Aβ25-35 (Figure 2B), indicating higher PKM2 levels. Altogether, TERT 
overexpressing cells demonstrate a shift towards glycolytic metabolism by altering 
protein levels of metabolic enzymes. 
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Figure 2B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2: Immunoblot analysis of metabolic markers reveals a shift towards glycolysis 
in TERT expressing cells following H2O2 and Aβ exposure.  
(A) HT22 cells were transfected with pcDNA or TERT plasmids followed by a 4 hour 
exposure to H2O2 (100 µM, 400 µM) or Aβ25-35 (25 µM).  Protein levels of metabolic 
enzymes (phospho-PDH/total PDH, PDK1, LDHA, PKM1/PKM2) were assessed by 
immunoblot analysis with the indicated antibodies. (B) Densitometric analysis of band 
intensity revealed significantly higher levels of phospho-PDH/PDH, PDK1 and LDHA and a 
lower protein ratio of PKM1/PKM2 in the TERT transfected cells compared to controls after 
oxidative stress treatments (100 µM H2O2, 400 µM H2O2, 25 µM Aβ25-35). The data 
presented are from three independent experiments ± SEM. Asterisk indicates significant 
difference (*, p≤ 0.05; **, p≤ 0.01; ***, p≤ 0.001; ****, p≤ 0.0001) tested by One-Way 
ANOVA followed by a Tukey test. 
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3.3 TERT expression prevents increases in mitochondrial ROS 
under oxidative stress  
Since the TERT overexpression plasmid did not have a fluorescent tag, cell cultures were 
co-transfected with a GFP plasmid at a 2:1 ratio (TERT:GFP) in order to identify 
transfected cells. It is presumed that cells with green fluorescence (GFP) will also contain 
the TERT overexpressing plasmid. HT22 cells were co-transfected with TERT + GFP 
and pcDNA + GFP plasmids, followed by a 12 hour exposure to 400 µM H2O2 or 25 µM 
Aβ25-35. Transfected cells were stained with MitoTracker Red CMXROS, a mitochondrial 
localized dye that emits red fluorescence in proportion to mitochondrial ROS levels, and 
visualized by fluorescence microscopy (Figure 3A,B). MitoTracker Red CMXROS 
fluorescence intensity of GFP positive cells was analyzed to determine differences 
between treatments (Figure 3C). Under control conditions, pcDNA and TERT transfected 
cells had comparable levels of ROS. However, when cells were exposed to 25 µM Aβ25-
35, TERT transfected cells had significantly lower levels of ROS compared to pcDNA 
transfected cells. Therefore, under oxidative stress conditions elicited by Aβ25-35 
exposure, cells overexpressing TERT have lower mitochondrial ROS levels. 
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Figure 3A 
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Figure 3C 
  
Figure 3: TERT overexpression reduces mitochondrial ROS levels following Aβ 
exposure. 
HT22 cells were co-transfected with GFP along with pcDNA or TERT plasmids 
followed by a 12-hour exposure to H2O2 (400 µM) or Aβ25-35 (25 µM).  TERT 
transfected cells were stained with MitoTracker Red CMXROS and visualized by 
fluorescence microscopy. Red (MitoTracker CMXROS), blue (Hoescht), white arrows 
(GFP positive cells). Representative photomicrographs of pcDNA (A) and TERT 
transfected cells (B). (C) Fluorescence intensity of GFP positive cells was quantified 
using Image J software. TERT overexpressing cells have a reduction in ROS levels 
under 400 µM H2O2 treatment and a significant reduction in ROS levels under 25 µM 
Aβ25-35 treatment compared to pcDNA transfected cells. The data presented are from 
three independent experiments ± SEM. Asterisk indicates significant difference (**, 
p≤0.01) tested by One-Way ANOVA followed by a Tukey test. Scale bars are 20 µm. 
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3.4 TERT overexpression promotes increased cell viability during 
oxidative stress 
HT22 cells were transfected with TERT or pcDNA plasmids, followed by a 24 hour 
exposure to 400 µM H2O2 or 25 µM Aβ25-35. Live cells were visualized by phase contrast 
microscopy (Figure 4A).  When cells were cultured under control conditions, TERT 
transfected cells had a higher confluency compared to pcDNA transfected cells. When 
stressed with 400 µM H2O2 or 25 µM Aβ25-35, TERT transfected cells maintained healthy 
morphology characterized by neuronal-like elongated processes protruding from the cell 
body. In contrast, increased cellular debris and morphologically stressed cells 
characterized by shrunken processes and rounding was observed in oxidant challenged 
pcDNA transfected cells. The MTT cell viability assay revealed that TERT transfected 
cells had significantly more cell viability under control and oxidative stress conditions 
compared to pcDNA transfected cells (Figure 4B).  These results confirm that TERT 
confers a survival advantage following oxidative stress induced by H2O2 or Aβ exposure. 
 
  
30 
 
Figure 4A 
50 μm 50 μm 50 μm 
50 μm 50 μm 50 μm 
Control 400 µM H2O2 25 µM Aβ 
pcDNA 
TERT 
31 
 
Figure 4B 
 
  
Figure 4: TERT confers a cell survivability advantage under H2O2 and Aβ induced 
stress.  
(A) Representative photomicrographs (200X magnification) of HT22 cells transfected with 
pcDNA or TERT plasmids followed by a 24 hour exposure to H2O2 (400 µM) or Aβ25-35 (25 
µM). (B) Cell viability was assessed using the MTT assay. TERT overexpressing cells had 
significantly higher cell viability under control, 400 µM H2O2 and 25 µM Aβ25-35 
treatments. The data presented are from three independent experiments ± SEM. Asterisk 
indicates significant difference (*, p≤0.05; **, p≤0.01) tested by One-Way ANOVA 
followed by a Tukey test. Scale bars are 50 µm. 
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Chapter 4: Discussion 
The present study provides evidence that TERT partially localizes to the mitochondria 
under H2O2 and Aβ-induced oxidative stress and alters metabolism in favour of 
glycolysis. By limiting mitochondrial metabolism, ROS production is significantly 
reduced and cell viability is improved.  TERT promotes a shift towards glycolysis within 
the first 4 hours of oxidative stress exposure, which is supported by changes in 
expression of metabolic enzymes such as an increase in the phospho-PDH/total PDH 
ratio, elevated levels of PDK1 and LDHA, and a decrease in the PKM1/PKM2 ratio. This 
is the first demonstration that TERT expression can promote altered levels of glycolytic 
enzymes during oxidative stress.  Up to 12 hours later, TERT overexpressing cells have 
decreased mitochondrial ROS production and have greater cell survivability at 24 hours 
after oxidative stress treatment compared to controls. These results indicate that aerobic 
glycolysis may be an important feature for TERT’s protective effects against oxidative 
stress. As previously discussed, elevated aerobic glycolysis allows neurons to become 
resistant to Aβ toxicity. This study offers evidence of a novel pro-survival mechanism 
mediated by TERT involving upregulation of aerobic glycolysis enzymes and a 
concomitant reduction of mitochondrial ROS production. A proposed mechanism is 
outlined in Figure 5. 
4.1 HT22 cell culture is an appropriate model to study AD  
The HT22 cell line is an immortalized mouse hippocampal neuronal cell line, developed 
from HT4 cells that were originally immortalized from primary mouse hippocampal 
neuronal cultures140. AD patients experience severe neurodegeneration and a decrease of 
volume of the hippocampus, which has critical functions in learning and memory141. The 
HT22 cell cultures recapitulate features of hippocampal neurons such as expression of 
cholinergic markers and glutamate sensitivity142,143. In addition, HT22 cells have been 
used extensively as a neuronal model to study oxidative stress induced by glutamate and 
H2O2 exposure
144–148. Furthermore, Aβ induced oxidative stress in HT22 cells has been 
previously used as a model to study neurotoxicity in Alzheimer’s disease149–153. However, 
there are some limitations of using an immortalized cell line to study the function of 
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neurons. HT22 cells are rapidly dividing cells that have a doubling time of approximately 
15 hours which may subject the cells to genetic drift as the cells divide, whereas neurons 
in the brain are post-mitotic. In addition, the brain is a complex structure consisting of 
various cell types, such as astrocytes and glia, and molecules that can act on neurons, 
such as neurotransmitters, which makes the physiology of neurons in the brain different 
from HT22 cell cultures. Future studies should use primary neuronal culture as a more 
physiologically relevant model to determine the protective effects of TERT. 
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Figure 5 
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Figure 5: Proposed mechanism of TERT mediated induction of aerobic glycolysis 
and protection from Aβ toxicity. 
Aβ can promote increased mitochondrial ROS by either activating p66Shc or directly 
interfering with the electron transport chain (ETC).  Elevated aerobic glycolysis confers 
protection from Aβ toxicity by reducing mitochondrial respiration while increasing the 
pentose phosphate pathway (PPP) with a resulting increase in antioxidant activity. An 
increase in aerobic glycolysis enzymes including PDK1, phospho-PDH/PDH and LDHA 
along with a decrease in PKM1/PKM2 protein levels was observed in TERT transfected 
cells exposed to Aβ. HIF1-α is known to promote aerobic glycolysis by increasing 
expression of the same metabolic enzymes induced by TERT expression. Hence, it is 
proposed that TERT may activate HIF1-α in the nucleus, or TERT may translocate to the 
mitochondria and bind to ND1 and ND2 coding regions which activates HIF1-α and 
prevents oxidative stress-induced damage. Alternatively, TERT may prevent activation of 
p66shc through JNK, or may directly interact with P-p66Shc in the mitochondria to 
prevent mitochondrial dysfunction. 
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4.2 TERT has partial localization to the mitochondria 
Immunofluorescence experiments illustrated that TERT localizes to the nucleus under 
control conditions and has partial localization with the mitochondria after 12 hours of 400 
µM H2O2 and 25 µM Aβ treatments. This is in agreement with previous studies that 
identified TERT expression in cultured hippocampal neurons as well as in control adult 
human hippocampal neurons46,135. Mitochondrial localization of TERT has also been 
previously confirmed under different cell types exposed to H2O2 stress and in 
hippocampal neurons derived from AD brains73,80,83,135,154. However contrary to previous 
research, the current study demonstrated that TERT is not completely excluded from the 
nucleus in the cells that exhibit mitochondrial localization. This effect may be due to the 
use of the FLAG-TERT plasmid that contains the FLAG epitope at the N-terminus of the 
TERT coding sequence, which may interfere with mitochondrial targeting and import of 
TERT.  
It has previously been determined that TERT has a maximum exclusion level of 60% 
from the nucleus after 24 hours in cancer cells154. Although it is suggested that oxidative 
stress promotes translocation of existing nuclear TERT to the mitochondria, this study 
does not address the possibility of cytosolic TERT that bypasses nuclear localization and 
is directly targeted to the mitochondria instead. Future studies should quantify FLAG-
TERT co-localization patterns in HT22 cells to determine if there is significant 
mitochondrial localization following H2O2 and Aβ oxidative stress treatments. In 
addition, subcellular fractionation and subsequent immunoblotting of nuclear, cytosolic 
and mitochondrial lysates could be performed to provide further support to localization 
patterns of TERT in HT22 cell cultures transfected with the TERT plasmid. Furthermore, 
time course experiments would provide insight to the maintenance of TERT in the 
mitochondria in HT22 cells and may eliminate the variability of nuclear exclusion 
observed in this study.  Finally, analysis of the localization patterns of endogenous TERT 
in a neuronal cell line would be ideal to rule out the possibility of mis-localization of 
highly expressed ectopic TERT following transient transfection. 
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4.3 TERT affects metabolism under oxidative stress 
4.3.1 TERT shifts metabolism towards aerobic glycolysis 
Enzymes involved in glycolysis were upregulated in TERT overexpressing cells exposed 
to low or high concentrations of H2O2 and Aβ induced oxidative stress. There was an 
increase in PDK1 protein levels and a concomitant increase in phospho-PDH/PDH ratio, 
indicating that upregulation of PDK1 expression promoted PDH phosphorylation.   
Phosphorylated PDH is inactive, thereby preventing the conversion of pyruvate to acetyl-
CoA, which is needed for the TCA cycle and the generation of NADH to fuel the electron 
transport chain in the inner mitochondrial membrane.  There was also an increase in 
LDHA protein levels, which catalyzes the conversion of pyruvate to L-lactate and limits 
the use of pyruvate for mitochondrial metabolism. Finally, there was a decrease in the 
PKM1/PKM2 ratio indicating higher PKM2 levels. Allosteric regulation allows PKM2 to 
switch from a high-activity tetrameric state to a low-activity dimeric state139. The dimeric 
form of PKM2 causes the accumulation of glycolytic intermediates and a shift towards 
the PPP, an alternative pathway for glycolysis that generates NADPH, a reducing agent 
used by antioxidant enzymes, ribose 5-phosphate needed for the synthesis of nucleotides, 
and erythrose 4-phosphate needed for the synthesis of aromatic amino acids. Altogether, 
these results demonstrate that TERT overexpressing cells combat H2O2 and Aβ induced 
oxidative stress by limiting mitochondrial OXPHOS and shifting towards a glycolytic 
phenotype.  In addition, the increased growth of TERT-overexpressing cells under 
control conditions may occur by TERT-mediated induction of aerobic glycolysis and 
anabolic metabolism typical of cancer cells. 
4.3.2 TERT may promote aerobic glycolysis by activation of HIF1-α  
A proposed mechanism for TERT’s ability to shift metabolism during oxidative stress 
may be through the activation of the alpha subunit of hypoxia induced factor 1 (HIF-1α). 
Many types of cancers have an upregulation of HIF1-α activity which is a transcription 
factor that increases expression of glucose transporters and enzymes within the glycolytic 
pathway155. HIF1-α is known to induce the expression of LDHA, which is critical for 
maintaining a reducing environment in order to combat ROS since it regenerates NAD+ 
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during the conversion of pyruvate to lactate, an essential co-factor for GAPDH, a key 
glycolytic enzyme that converts glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate156. HIF1-α also directly elevates PDK1 levels which limits the 
conversion of pyruvate to acetyl-CoA to be used for OXPHOS, thereby shifting towards 
glycolysis156. Furthermore, PKM2 has been reported to translocate to the nucleus to 
promote the activation of HIF1-α and increased transcription of PKM2 in a feed forward 
mechanism to alter metabolism157. Previously, HIF1-α has been linked to TERT as a 
transcriptional regulator and can bind to the hTERT proximal promoter region through 
two HIF-1α consensus binding sites to activate TERT transcription and enhance TERT 
expression158–160. In addition, murine embryonic stem cells rely on HIF-1α to promote 
TERT expression and maintain telomere length161.  
However, the relationship between TERT and HIF-1α is yet to be explored in neurons 
and other post-mitotic cells. In the current study, oxidative stress induced with H2O2 or 
Aβ was unable to increase endogenous TERT expression in the HT22 cells, given that 
there were no immunoreactive bands on Western blots probed with anti-TERT antibodies 
in cell extracts from pcDNA transfectants. Therefore, it is possible that TERT acts as an 
activator of HIF1-α instead. Mutations in the subunit ND2 of complex I has been shown 
to increase ROS levels leads to a subsequent increase in HIF1-α levels in head and neck 
squamous cell carcinoma162. Interestingly, TERT binds to mitochondrial DNA at the 
coding region for ND2 and protects against oxidative stress-induced damage in human 
umbilical vein endothelial cells, however the mechanism is unknown80. It is possible that 
the binding of TERT to mitochondrial DNA at the coding region for ND2 may activate 
HIF1-α to initiate metabolic changes that are protective against oxidative stress. Future 
research should determine whether TERT can affect HIF-1α activity during oxidative 
stress to elucidate potential feed-forward mechanisms for the metabolic changes caused 
by TERT overexpression. 
4.3.3 TERT may promote aerobic glycolysis by preventing activation of p66Shc 
Another mechanism for the TERT-induced shift in metabolism may be via inhibition of 
the 66-kilodalton isoform of the adaptor protein Src homology 2 domain containing 
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protein (p66Shc), which plays major roles in redox balance, oxidative stress and 
apoptosis163. Following phosphorylation on serine 36, p66Shc translocates to the 
mitochondria where it increases mitochondrial ROS production and perturbs 
mitochondrial membrane potential in favour of cytochrome C release164.  Furthermore, 
p66Shc has been linked to neurodegeneration via the opening of the permeability 
transition pore (PTP) located on the OMM, which is a key event to initiate apoptosis165. 
Phosphorylation of p66Shc can be achieved by kinases PKCβ and Jun NH2-terminal 
kinase (JNK) which are activated by oxidative stressors such as H2O2 and Aβ 
respectively166,167. In addition, p66Shc activation leads to a reduction in antioxidant 
enzymes such as SOD, GPx and catalase, which further renders the cell susceptible to 
toxic levels of ROS168. Interestingly, recent studies demonstrate that cells lacking p66Shc 
shift their metabolism away from mitochondrial OXPHOS and towards aerobic 
glycolysis, along with an increase in lactate production169,170. TERT may be able to shift 
metabolism towards glycolytic pathways by preventing phosphorylation and subsequent 
activation of p66Shc under oxidative stress conditions. Studies in our lab have shown that 
Aβ can trigger phosphorylation and activation of p66Shc in HT22 cells (unpublished 
observations).  Moreover, inhibition of p66Shc expression leads to elevated aerobic 
glycolysis and decreased sensitivity to Aβ toxicity.  TERT has been shown to supress 
caspase mediated apoptosis, and this is dependent on phosphorylation of JNK171.  TERT 
inhibition of JNK activation, and subsequent p66Shc phosphorylation, may promote a 
shift towards aerobic glycolysis, decreased ROS production, and increased cell viability 
under Aβ-induced oxidative stress. In addition, since localization of p66Shc and TERT 
converge in the mitochondria, it is possible that TERT may directly interact with p66Shc 
to prevent its phosphorylation and subsequent activation. Future studies should explore 
whether TERT directly or indirectly influences p66Shc activation and explore possible 
interactions between TERT and p66Shc within the mitochondria. 
4.3.4 Metabolic alterations in TERT-deficient and TERT-overexpressing mice  
Although the current study focuses on a cell culture model to examine the metabolic 
effects of TERT under oxidative stress conditions, in vivo studies support the finding that 
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TERT may alter metabolism and mitochondrial function. Metabolic changes in TERT-
deficient and TERT-overexpressing mice are reviewed below. 
First generation TERT knockout mice have no changes to fertility or identifiable 
phenotypic change172. However, later generations have a significant reduction in telomere 
length and lifespan compared to wild-type, leading to atrophy and functional decline of 
proliferative (ex. intestine) as well as quiescent (ex. liver) organs, and infertility by the 
fourth to sixth generation (G4-G6)173,174. Interestingly, G4 TERT-deficient mice have 
severe metabolic and mitochondrial changes, especially in networks regulated by the 
alpha and beta of peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-
1α and PGC-1β), which control mitochondrial biogenesis and metabolic processes such 
as OXPHOS, gluconeogenesis, fatty acid metabolism and β-oxidation175. When the liver 
and heart mitochondria of G4 mice were examined, there was repression of OXPHOS 
genes from all five ETC complexes, reduced activity of ETC complexes, reduced oxygen 
consumption, decreased ATP synthesis, decreased levels of antioxidant enzymes 
(catalase, GPx, SOD1) and increased mitochondrial ROS production174. In a separate 
study, when G4 mice were fed a high fat, high sucrose diet for 8 weeks, there was 
increased insulin resistance and glucose intolerance in liver and muscle tissue compared 
to controls176.  
TERT overexpressing mice exhibit improvement in metabolic decline during aging. 
Constitutive expression of TERT in a mouse with a cancer resistant background was 
shown to have delayed telomere shortening and an extension of median lifespan 
accompanied by a youthful physiological profile, including delayed degenerative and 
inflammatory age-related pathologies of organs such as the skin, intestine, kidney, liver 
and brain177. In addition, these mice had improved glucose tolerance compared to aged 
wild type controls177. When a metabolic profile of wild-type young and aged mice was 
compared to the same TERT overexpressing cancer-resistant mice, aged TERT 
overexpressing mice had a younger metabolic age compared with wild-type mice of the 
same chronological age178. The same effect held true for aged mice receiving TERT gene 
therapy via adeno associated virus vectors (AAV) in various stratified epithelia179. When 
adult and old mice were given two months of TERT gene therapy, researchers observed 
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improved insulin sensitivity and glucose tolerance, along with a reversal of the metabolic 
signature associated with aging compared to age matched wild-type mice178,179.  
Studies using TERT-deficient and TERT-overexpressing mice have provided evidence 
supporting TERT’s ability to delay aging and to alter the metabolic profile of an 
organism. However, research into the effect of TERT-deficiency or TERT-
overexpression on the metabolism of brain cells in vivo is lacking. In addition, it is 
difficult to determine whether the protective effects observed in TERT-overexpressing 
mice rely on restoring telomerase activity or if non-canonical functions of TERT are at 
play. Based on the results of the present study, TERT-overexpression may be able to 
improve age-related oxidative damage and neurodegeneration by altering metabolism in 
favour of aerobic glycolysis, however this is yet to be confirmed in vivo. 
4.4 TERT alleviates mitochondrial ROS production 
The decrease in ROS production under H2O2 and Aβ oxidative stress treatments in TERT 
overexpressing cells corroborates previous research, although a mechanism is still 
speculative. As previously discussed, TERT can decrease ROS through improving 
respiratory chain activity by decreasing succinate-linked respiration, complex I and IV 
activity and UCP2 expression73,80,81. TERT has also been shown to increase the 
availability of glutathione for GPx activity as well as promote more rapid recovery of 
peroxidases from a hyperoxidized state81.  
The change in PKM1/PKM2 protein levels in TERT overexpressing cells during H2O2 
and Aβ treatments levels suggests a metabolic mechanism for alleviating ROS production 
under oxidative stress treatment. As previously described, allosteric regulation allows 
PKM2 to switch from a high-activity tetrameric state to a low-activity dimeric state139. 
The dimeric form of PKM2 causes the accumulation of glycolytic intermediates and  a 
shift towards the PPP, which is an alternative pathway for glycolysis that promotes the 
synthesis of nucleotides and aromatic amino acids180. The PPP also produces the reducing 
factor NADPH that can be used for antioxidant enzymes and to recycle the anti-oxidant 
glutathione needed for GPx activity, which may further contribute to the decreased ROS 
effect observed in this study. Additional support arises from previous studies that 
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demonstrate TERT overexpressing cells have higher reduced versus  oxidized glutathione 
compared to control cells81.  
Future experiments should assess levels of NADPH in TERT overexpressing cells under 
oxidative stress conditions to confirm if there is an upregulation of the PPP. In addition, 
levels of reduced glutathione and GPx activity should be assessed to determine if changes 
in antioxidant activity contributes to a reduction in ROS levels observed under Aβ 
exposure in TERT overexpressing cells. 
4.5 TERT improves cell viability 
The MTT assay was used to reveal that TERT overexpressing cells have increased cell 
viability and proliferative capacity under control and H2O2 or AB oxidative stress. 
Immunofluorescence experiments illustrated that TERT localizes to the nucleus under 
control conditions and has partial localization with the mitochondria under H2O2 and AB 
oxidative stress treatments. This suggests that TERT may have nuclear as well as 
mitochondrial functions that contribute to cell viability and proliferation.  
4.5.1 TERT overexpression may reconstitute telomerase activity 
Since TERC expression or telomerase activity was not tested in the current study, it is 
possible that overexpression of TERT may reconstitute telomerase activity in 
combination with endogenous TERC. This may lead to telomere elongation and a 
subsequent increase in proliferative capacity of cells, as is expected with TERT’s 
canonical function. Recently, an alternative TERC has been identified in the mouse brain 
and has been shown to interact with both mouse and human versions of TERT, leading to 
an increase in telomerase activity and increased cell survivability under H2O2 oxidative 
stress181. Therefore, there is also the possibility of an alternative TERC present in the 
mouse HT22 cell line that may reconstitute telomerase activity and contribute to 
increased cell viability and proliferation in TERT overexpressing cells. Additional 
experiments should be performed to ascertain TERC expression in HT22 cells and 
whether overexpression of TERT restores telomerase activity and extends telomeres.  
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4.5.2 TERT may have nuclear functions that contribute to cell viability 
While it is possible that telomerase activity may contribute to improved cell viability, 
previous research suggests that TERC expression is absent from hippocampal neurons 
which express TERT46. Therefore, it is possible that TERT may influence cell viability in 
HT22 cells in a TERC-independent manner. As previously discussed, TERT may act as a 
transcription factor in the nucleus to increase the expression of genes involved in cell 
growth and proliferation48. TERT interacts with p65 and p50 to influence transcription of 
target genes of the redox sensitive transcription factor NF-κB55. Furthermore, estrogen 
receptor activation was shown to increase TERT’s association with p65 and NF-κB  and 
protect against Aβ toxicity182. It is known that NF-κB can influence transcription of 
antioxidants such as Mn SOD, metallothionein and glutathione-S-transferase183. 
Therefore, TERT may be exerting its pro-survival effects through upregulating the 
transcription of antioxidants targeted by NF-κB. Alternatively, TERT can increase 
transcription of genes in the Wnt/β-catenin signalling pathway which is involved in stem 
cell proliferation and self-renewal57. In addition to transcriptional regulation, TERT may 
contribute to telomere capping and chromosomal structure, independent of telomere 
lengthening58–61. To determine if TERT acts as a transcription factor to increase the 
expression of pro-survival genes, future studies could use DNA microarrays or RNA-Seq 
to identify genes that are upregulated or downregulated under H2O2 and Aβ induced 
oxidative stress in TERT overexpressing cells. 
4.5.3 TERT may have mitochondrial functions that contribute to cell viability 
It is highly probable that TERT’s effect on cell viability arises from its mitochondrial 
localization, since the mitochondria controls the cell’s intrinsic apoptosis pathway. As 
previously discussed, TERT inhibition increases CC3 expression, decreases Bcl-2/Bax 
ratio expression and reduces mitochondrial membrane potential in cultured neurons under 
oxygen and glucose deprivation98. In addition, it was shown that TERT upregulated Bcl-2 
and downregulated Bax and p53 in rat spinal cord motor neurons; events linked to TERT-
mediated anti-apoptotic effects99. Furthermore, it was established that TERT maintained 
mitochondrial membrane potential in mouse hippocampal neurons exposed to Aβ133. 
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Therefore, levels of Bcl-2/Bax, p53 and cleaved caspases as well as mitochondrial 
membrane potential should be measured to determine if supressing the intrinsic apoptosis 
pathway is a mechanism owing to the observed increase in cell viability in TERT 
overexpressing cells under H2O2 and Aβ oxidative stress. 
 
 
 
4.6 TERT is a potential therapeutic for Alzheimer’s Disease 
4.6.1 Aβ25-35 treatment has the same effect as other Aβ species 
It has been established that Aβ1-42 and Aβ1-40 are the predominant forms of Aβ within 
insoluble extracellular plaques that interfere with cognitive function in AD184,185. 
However, racemization of Aβ1-40 causes the in vivo conversion to the toxic Aβ25-35 
fragment, which is also present in senile plaques and degenerated CA1 neurons in AD 
brains186. It has been proposed that Aβ25-35 is the biologically active region responsible 
for Aβ toxicity, since it is the shortest fragment able to form stable B-sheet aggregates 
and induce neurotoxicity40–42. Similar to Aβ1-42, Aβ25-35 is able to spontaneously 
transform from soluble oligomers to aggregated fibrils and the monomeric form of Aβ25-
35 is also cytotoxic
190–192. A previous study has also characterized the effect of Aβ species 
on rat brain mitochondria and reported similar effects with exposure to Aβ1-42 or Aβ25-35. 
Both Aβ peptides accumulated in the mitochondria, caused declines in respiratory chain 
complexes I, II and IV activity, and increased mitochondrial membrane viscosity, all 
resulting in a strong inhibition of ATP synthesis193. In addition, there was an increase of 
cytochrome C release upon Aβ1-42 or Aβ25-35 exposure193. Furthermore, additional studies 
observed that Aβ1-40 or Aβ25-35 exposure results in pro-apoptotic effects such as increased 
cleaved caspase 3 and 8, reduced Bcl-2/Bax protein ratio, loss of mitochondrial 
membrane potential and mitochondrial DNA damage in murine cerebrovascular 
endothelial cells132,194. Therefore, Aβ25-35 is an appropriate model to study the toxic 
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effects of full length Aβ1-42 and it is expected that results generated with Aβ25-35 in this 
study would yield parallel findings if other toxic species of Aβ were used.  However, it 
would still be worthwhile to compare the ability of exogenously expressed TERT to 
protect against toxicity elicited by various species of Aβ1-42. 
4.6.2 Metabolic alterations in AD may be mitigated with TERT 
As previously described, patients with AD have reduced glucose uptake, altered glucose 
metabolism and damage to mitochondrial components of OXPHOS110,111,113. These 
metabolic characteristics are also reflected in transgenic mouse models of AD that 
express the mutant forms of human genes encoding APP or PSEN1 to promote 
amyloidogenic processing of the Aβ peptide. Researchers observe a downregulation of 
mitochondrial biogenesis, decrease in activity and expression of OXPHOS complexes, 
impaired glucose tolerance, and reduced insulin sensitivity in the hippocampus of 3 and 6 
month old transgenic AD mice195. Thus, targets that combat the early metabolic changes 
in hippocampal neurons caused by Aβ accumulation may prove to be effective in 
delaying the progression of AD. The current study demonstrates that TERT is protective 
against Aβ induced oxidative stress in a hippocampal neuronal cell line by altering 
metabolism away from OXPHOS and towards aerobic glycolysis, leading to reduced 
mitochondrial ROS production and improved cell viability.  Given the results of this 
study and previous studies that show mouse models using TERT gene therapy improves 
glucose tolerance and insulin sensitivity, it stands to reason that TERT overexpression 
may also be beneficial to mitochondrial function of hippocampal neurons exposed to Aβ 
in vivo.  
4.6.3 TERT can be used as a therapeutic agent without increasing cancer 
TERT overexpression in somatic cells increases replicative lifespan of cells, but no 
transformation to a malignant cancer phenotype occurs, even in the presence of 
oncogenic HRAS expression196. Similar studies have confirmed that TERT 
overexpressing somatic cells respond normally to contact inhibition, cell-cycle 
checkpoints and growth arrest treatments and do not form tumors when injected into 
mice, even when 10 times the amount of cells are used197–199. A possible explanation for 
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this may be that most tumors with elevated hTERT expression occur after a mutation 
arises in the tumor suppressor p53 gene, indicating that multiple mutations are needed for 
a malignant phenotype37. These findings also extend to animal models. When adult and 
old mice were given TERT gene therapy via adeno associated virus vectors (AAV), 
researchers observed improved insulin sensitivity and glucose intolerance, decreased 
incidence of osteoporosis, improved neuromuscular and object-recognition tasks and 
extended lifespan, all without increasing tumorigenic activity179. Therefore, given the 
evidence of TERT’s protective effects against Aβ toxicity presented in this study, ectopic 
TERT expression could possibly be used as a therapeutic for AD and other 
neurodegenerative diseases. 
4.7 Final Remarks and Future Directions 
The current study demonstrates that TERT partially localizes to the mitochondria under 
H2O2 and Aβ induced oxidative stress and causes a shift in metabolism towards aerobic 
glycolysis. In addition, mitochondrial ROS production was lessened during toxic Aβ 
exposure and cell viability was improved with TERT overexpression. While these results 
illustrate that TERT is protective against H2O2 and Aβ toxicity, further research is needed 
to determine the mechanisms behind this effect.  
Although one may argue that aerobic glycolysis is inefficient at producing ATP 
compared to the mitochondria when measured per unit glucose, studies have proven that 
the rate of ATP production through aerobic glycolysis is comparable to OXPHOS200,201. 
While changes to metabolic enzymes in TERT overexpressing cells during oxidative 
stress conditions provides compelling evidence in favour of aerobic glycolysis, future 
experiments should measure glucose uptake, lactate production and oxygen consumption 
to confirm. In addition, the rates of glycolysis versus OXPHOS should be measured using 
other methods (Ex. Seahorse XF24 Analyzer) to confirm an increase in aerobic glycolysis 
following oxidative stress treatment in TERT overexpressing cells.  
It is not entirely clear whether nuclear or mitochondrial localization of TERT is providing 
the observed benefits against oxidative stress. TERC expression and telomerase activity 
should be assessed in TERT overexpressing cells to determine if TERT’s canonical 
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function in the nucleus provides protection under H2O2 and Aβ induced oxidative stress. 
In addition, modifications to TERT can be used to alter organelle localization. An 
exclusively mitochondrial TERT could be engineered with a constitutive mitochondrial 
targeting sequence at the amino terminus and deletion of the nuclear localization signal at 
amino acid residues 222-240. Alternatively, nuclear export of TERT can be inhibited by 
increasing activity of Shp2 or the 14-3-3 signalling protein along with deletion of the 
nuclear export signal located at the C-terminus of TERT. Furthermore, the RT domain of 
TERT should be removed or mutated to determine whether the protective effects are 
dependent on the catalytic function of TERT. Then, protein levels of metabolic enzymes, 
mitochondrial ROS production and cell viability can be assessed after exposure to toxic 
levels of H2O2 and Aβ in HT22 cell cultures overexpressing either nuclear-
/mitochondrial- targeted and inactive/active TERT.  
Due to the previous literature on TERT’s non-canonical mitochondrial functions, it would 
be promising if the same metabolic shift, alterations in mitochondrial ROS production, 
and changes in cell viability are observed with overexpression of a TERT protein 
engineered to be constitutively mitochondrially located. The observation of TERT’s 
ability to promote aerobic glycolysis under Aβ-induced oxidative stress suggests that 
TERT gene or protein therapy may be a therapeutic for AD. However, further research is 
needed to elucidate the mechanisms behind TERT’s metabolic and mitochondrial 
functions in hippocampal neurons in vitro and in vivo. 
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Appendix: Supplemental Figures and Tables 
 
TERT Reverse primer- 5'{AGGTGAACCAGCACGTCG}3' 
CCCCCCNTATTGACGTCAATGNNCGGNNAAAATGGCCCGCCTNGNCNNTNATNNCCAGTACATGACCTNNTGNGACTT
TCCTACTNGNCAGTACANNNNACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTNGGCAGTACATCAATGGGCG
NNGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAAT
CAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTC
TATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGG
AGACCCAAGCTTGGTACCAACATGGACTACAAGGACGACGATGACAAGGGAATTCCCGGGTCGACCCACGCGTCCGGG
CAGCGCTGCGTCCTGCTGCGCACGTGGGAAGCCCTGGCCCCGGCCACCCCCGCGATGCCGCGCGCTCCCCGCTGCCGA
GCCGTGCGCTCCCTGCTGCGCAGCCACTACCGCGAGGTGCTGCCGCTGGCCACGTTCGTGCGGCGCCTGGGGCCCCAGG
GCTGGCGGCTGGTGCAGCGCGGGGACCCGGCGGCTTTCCGCGCGCTGGTGGCCCAGTGCCTGGTGTGCGTGCCCTGGG
ACGCACGGCCGCCCCCCGCCGCCCCCTCCTTCCGCCAGGTGTCCTGCCTGAAGGAGCTGGTGGCCCGAGTGCTGCAGAG
GCTGTGCGAGCGCGGCGCGAAGAACGTGCTGGCCTTCGGCTTCGCGCTGCTGGACGGGGCCCGCGGGGGCCCCCCCGA
GGCCTTCACCACCAGCGTGCGCAGCTACCTGCCCAACACGGTGACCGACGCACTGCGGGGGAGCGGG 
TERT Forward primer- 5'{CCCTCTGCTACTCCATCCTG}3' 
CGCTGGGGGCCAGGGCGCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCAA
GCTGACTCGACACCGTGTCACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAGACGCAGCTGAGTCGGAAGCT
CCCGGGGACGACGCTGACTGCCCTGGAGGCCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACGA
CTACAAGGACGACGATGACAAGTGATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGC
CTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTC
CCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGT
GGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTG
AGGCGGAAAGAACCAGTGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAA
AGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCA
TCACAAAAATCGACGCTCAAGTCAGANGTGGCGAANCCCGACAGGACTATNAAGATACCAGGCGTTTCCCCCTGGAAG
CTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACNGGATANCTGTNCGCCTTTCTCCCTTNNGGAAGCGNGGCGC
TTTCTCATAGCTCACGCTGNAGGTATCTCAGTTCGGTGTANGTCGTTCGCTCCAAG 
Appendix 1: Sequencing Information of FLAG-TERT overexpression plasmid. 
The 071 plasmid (referred to as FLAG-TERT) overexpression plasmid was provided 
without a plasmid map so sequencing was performed by creating TERT Forward and 
TERT Reverse primers to confirm coding of the FLAG epitope and the TERT protein. 
The resulting sequencing information is provided in the 5’ to 3’ direction. Sequencing 
revealed a FLAG epitope at the N- and C- terminus of TERT coding regions. Potential 
start codons are highlighted in yellow. 
hCMV Promoter 
FLAG Epitope 
T7 Promoter 
hTERT sequence 
hTERT sequence 
FLAG Epitope SP6 Promoter 
BGH Terminator 
pMB1 ori 
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TERT Reverse primer- 5'{AGGTGAACCAGCACGTCG}3' 
GANCATGGAGANCNNNNNNTTTGCGGGGNTTNNNNCGGGACGGGCTNNNTCNTGCNTTTTGNTGGATGANTTTCTNGT
TGGTGACACNNCACNTCACCCCACGCGAAAACCTTCCTCAGGACCNTGNTCCGAGNNTGTCCCTGAGTATGGCTGCGT
GGTGAACTTGCGGAAGACAGTGGTGAACTTNCCCTGTAGAAGACGAGGCCCTGGGTGGCACGGCTTTTGTTCAGATGC
CGGCCCACGGCCTATTCCCCTGGTGCGGCCTGNTGCTGGATACCCGGACCCTGGAGGTGCAGAGCGACTACTCCAGCTA
TGCCCGGACCTCCATCAGAGCCAGTCTCACCTTCAACCGCGGCTTCAAGGCTGGGAGGAACATGCGTCGCAAACTCTTT
GGGGTCTTGCGGCTGAAGTGTCACAGCCTGTTTCTGGATTTGCAGGTGAACAGCCTCCAGACGGTGTGCACCAACATCT
ACAAGATCCTCCTGCTGCAGGCGTACAGGTTTCACGCATGTGTGCTGCAGCTCCCATTTCATCAGCAAGTTTGGAAGAA
CCCCACATTTTTCCTGCGCGTCATCTCTGACACGGCCTCCCTCTGCTACTCCATCCTGAAAGCCAAGAACGCAGGGATG
TCGCTGGGGGCCAAGGGCGCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCA
AGCTGACTCGACACCGTGTCACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAGACGCAGCTGAGTCGGAAGC
TCCCGGGGACGACGCTGACTGCCCTGGAGGCCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACG
ACTACAAGGACGACGATGACAAGTGATCTAGAGGG 
 TERT Forward primer- 5'{CCCTCTGCTACTCCATCCTG}3' 
CGCTGNNGGCNNAGGGCGCCGCCGGCCCTCTGCCCTCCGAGGCCGTGCAGTGGCTGTGCCACCAAGCATTCCTGCTCA
AGCTGACTCGACACCGTGTCACCTACGTGCCACTCCTGGGGTCACTCAGGACAGCCCAGACGCAGCTGAGTCGGAAGC
TCCCGGGGACGACGCTGACTGCCCTGGAGGCCGCAGCCAACCCGGCACTGCCCTCAGACTTCAAGACCATCCTGGACG
ACTACAAGGACGACGATGACAAGTGATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCA
GCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCAC
TCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGG
GTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTC
TGAGGCGGAAAGAACCAGTGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCA
AAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATANGCTCCGCCCCCCTGACGAG
CATCNCAAAANNCGACGCTCAAGTCAGANGTGGCGAANCCCGACAGGANTATAAAGATACCAGGCGTTTCCCCCTGGN
AANCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTA 
 
Appendix 2: Sequencing Information of TERT overexpression plasmid. 
The 072 (referred to as TERT) overexpression plasmid was provided without a plasmid 
map so sequencing was performed by creating TERT Forward and TERT Reverse 
primers to confirm coding of the TERT protein. The resulting sequencing information is 
provided in the 5’ to 3’ direction. Although sequencing revealed a FLAG epitope at the 
C-terminus of TERT, anti-FLAG antibodies could not detect FLAG by Western blot or 
by immunofluorescence in 072 (TERT) transfected cells. 
hTERT sequence 
FLAG Epitope SP6 Promoter 
BGH Terminator 
pMB1 ori 
hTERT sequence 
FLAG Epitope 
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Antibodies and Dyes 
Target Host Company Catalogue Number 
hTERT Rabbit polyclonal Rockland 600-401-252S 
FLAG Mouse monoclonal Sigma F3165 
TOM20 Rabbit polyclonal Santa Cruz sc-11415 
PDH Mouse monoclonal abcam ab110334 
pSer232 PDH Rabbit polyclonal EMD Millipore AP1063 
PDK1 Rabbit polyclonal Enzo Life Sciences ADI-KAP-PK112-F 
LDHA Rabbit polyclonal Cell Signalling #2012 
PKM1 Rabbit monoclonal Cell Signalling #7067 
PKM2 Rabbit polyclonal Cell Signalling #3198 
HRP-conjugated 
secondary mouse 
Goat Santa Cruz sc-2030 
HRP-conjugated 
secondary rabbit 
Goat Santa Cruz sc-2005 
Alexa Fluor 488 
Goat anti-mouse 
polyclonal 
Sigma R37120 
Alexa Fluor 594 
Goat anti-rabbit 
polyclonal 
Sigma A-11008 
MitoTracker 
CMXROS 
--- Invitrogen M7512 
MTT --- Sigma M2003 
DAPI (ProLong 
Antifade Mountant 
with DAPI) 
--- Invitrogen P36962 
 
Appendix 3: Table 1: List of antibodies and dyes. 
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Appendix 4: pcDNA transfected cells do not exhibit anti-FLAG immunoreactivity 
following immunofluorescence staining. 
Immunofluorescence staining of HT22 cells transfected with the pcDNA expression 
construct.  Cells were exposed to H2O2 (400 µM) or Aβ25-35 (25 µM) for 12 hours post-
transfection and stained with anti-FLAG and anti-TOM20 antibodies. There is no visible 
FLAG fluorescence in all treatments.  (Green (FLAG), Red (TOM20), blue (DAPI). 40X 
objective lens. Scale bars are 30 µm. 
  
pcDNA 
Control 
pcDNA 
400 µM  
H
2
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2
 
pcDNA 
25 µM  
Aβ 
TOM20 + DAPI FLAG 
30 µm 
30 µm 
30 µm 30 µm 
30 µm 
30 µm 
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Appendix 5: Dose Response Curve of HT22 cells following H2O2 exposure.  
HT22 cells were seeded in 96 well plates at 7,000 cells/well then exposed to the indicated 
concentrations of H2O2 for 24 hours.  Cell viability was determined using the MTT assay 
and expressed as a percentage of untreated cells.  The LD50 was determined to be 0.67 
mM. 
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